-
Press ReleaseNovartis ianalumab receives FDA Breakthrough Therapy designation for Sjögren’s disease
-
Press ReleaseNovartis and US government reach agreement on lowering drug prices in the US
-
Press ReleaseNovartis ianalumab first drug to reduce disease activity and patient burden in Sjögren’s disease Phase III trials
-
Press ReleaseNovartis showcases significant immunology advancements in ACR congress with new data in complex autoimmune diseases
-
Press ReleaseNovartis Cosentyx® meets primary and all secondary endpoints in Phase III trial in patients with polymyalgia rheumatica (PMR)
-
Press ReleaseNovartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU)
-
Press ReleaseNovartis to launch Direct-to-Patient platform for Cosentyx® (secukinumab) in the US
-
Press ReleaseNovartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease
-
Press ReleaseNovartis provides update on Phase III GCAptAIN study of Cosentyx® in giant cell arteritis (GCA)
-
Press ReleaseNovartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN)
-
Press ReleaseFDA approves Novartis radioligand therapy Pluvicto® for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer
-
Press ReleaseNew Novartis Phase III data demonstrate meaningful efficacy and safety results of intrathecal onasemnogene abeparvovec in broad patient population with SMA